Widespread increases in malondialdehyde immunoreactivity in dopamine-rich and dopamine-poor regions of rat brain following multiple, high doses of methamphetamine

Frontiers in Systems Neuroscience

Volumn , Issue MAY 2011, 2011, Pages

  Horner, Kristen A ^a   Gilbert, Yamiece E ^a   Cline, Susan D ^a  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Lipid peroxidation; Neurotoxicity; Psychostimulant; Striatum; Substantia nigra

Indexed keywords

DOPAMINE; MALONALDEHYDE; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CAUDATE NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; OXIDATIVE STRESS; PUTAMEN; RAT; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

EID: 84856170894     PISSN: 16625137     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnsys.2011.00027     Document Type: Article

References (60)

1. Acikgoz, O., Gonenc, S., Kayatekin, B. M., Uysal, N., Pekcetin, C., Semin, I., and Gure, A. (1998). Methamphetamine causes lipid peroxidation and an increase in superoxide dismutase activity in the rat striatum. Brain Res. 813, 200-202.
2. Aldini, G., Dalle-Donne, I., Facino, R. M., Milzani, A., and Carini, M. (2007). Intervention strategies to inhibit protein carboxylation by lipoxidation-derived reactive carbonyls. Med. Res. Rev. 27, 817-868.
3. Bakhit, C., Morgan, M. E., Peat, M. A., and Gibb, J. W. (1981). Long-term effects of methamphetamine on synthesis and metabolism of 5-hydroxytryptamine in various regions of the rat brain. Neuropharmacology 20, 1135-1140.
4. Baxter, L. R. Jr., Schwartz, J. M., Phelps, M. E., Mazziotta, J. C., Guze, B. H., Selin, C. E., Gerner, R. H., and Sumida, R. M. (1989). Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatry 46, 243-250.
5. Brown, J. M., Quinton, M. S., and Yamamoto, B. K. (2005). Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrate. J. Neurochem. 95, 429-436.
6. Brown, J. M., and Yamamoto, B. K. (2003). Effects of amphetamine on mitochondrial function: role of free radicals and oxidative stress. Pharmacol. Ther. 99, 45-53.
7. Burke, W. J., Li, S. W., Chung, H. D., Ruggiero, D. A., Kristal, B. S., Johnson, E. M., Lampe, P., Kumar, V. B., Franko, M., Williams, E. A., and Zahm, D. S. (2004). Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25, 101-115.
8. Burke, W. J., Li, S. W., Williams, E. A., Nonneman, R., and Zahm, D. S. (2003). 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res. 989, 205-213.
9. Bush, G., Luu, P., and Posner, M. I. (2000). Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn. Sci. 4, 215-222.
10. Bustamante, D., You, Z. B., Castel, M. N., Johansson, S., Goiny, M., Terenius, L., Hokfelt, T., and Herrera-Marschitz, M. (2002). Effect of single and repeated methamphetamine treatment on neurotransmitter release in substan-tia nigra and neostriatum of the rat. J. Neurochem. 83, 645-654.
11. Cadet, J. L., Subramaniam, J., and Deng, X. (2003). Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J. 17, 1775-1788.
12. Chapman, D. E., Hanson, G. R., Kessner, R. P., and Keefe, K. A. (2001). Long- term changes in basal ganglia function after a neurotoxic regimen of methamphetamine. J. Pharmacol. Exp. Ther. 296, 520-527.
13. Chéramy, A., Leviel, V., and Glowinski, J. (1981). Dendritic release of dopamine in the substantia nigra. Nature 289, 537-542.
14. Choe, E. S., Chung, K. T., Mao, L., and Wang, J. Q. (2002). Amphetamine increases phosphorylation of extracellular signal-regulated kinase and transcription factors in the rat striatum via group I metabotropic glutamate receptors. Neuropsychopharmacology 27, 565-575.
15. Clow, D. W., and Hammer, R. P. Jr. (1991). Cocaine abstinence following chronic treatment alters cerebral metabolism in dopaminergic reward regions; bromocriptine enhances recovery. Neuropsychopharmacology 4, 71-75.
16. Del Rio, D., Stewart, A. J., and Pellegrini, N. (2005). A review of recent studies on malondialdehyde as a toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Res. 15, 316-328.
17. Emson, P. C., Koob, G., and Iversen, L. L. (1977). Origin of dopaminergic affer-ents to the rat frontal cortex [proceed-ings]. Br. J. Pharmacol. 60, 270P-271P.
18. Fitzmaurice, P. S., Tong, J., Yazdanpanah, M., Liu, P. P., Kalasinsky, K. S., and Kish, S. J. (2006). Levels of 4-hydroxynonenal and malondialde-hyde are increased in brain of human chronic users of methamphetamine. J. Pharmacol. Exp. Ther. 319, 703-709.
19. Gerfen, C. R., and Bolam, J. P. (2010). "The neuroanatomical organization of the basal ganglia," in Handbook of Basal Ganglia Structure and Function, eds H. Steiner and K. Y. Tseng (New York, NY: Academic Press), 3-23.
20. Gluck, M. R., Moy, L. Y., Jayatilleke, E., Hogan, K. A., Manzino, L., and Sonsalla, P. K. (2001). Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J. Neurochem. 79, 152-160.
21. Green, A. R., De Souza, R. J., Williams, J. L., Murray, T. K., and Cross, A. J. (1992). The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlormethia-zole. Neuropharmacology 31, 315-321.
22. Grimm, J., Mueller, A., Hefti, F., and Rosenthal, A. (2004). Molecular basis for catecholaminergic neuron diversity. Proc. Natl. Acad. Sci. U.S.A. 101, 13891-13896.
23. Heeringa, M. J., and Abercrombie, E. D. (1995). Biochemistry of somatoden-dritic dopamine release in substantia nigra: an in vivo comparison with stri-atal dopamine release. J. Neurochem. 65, 192-200.
24. Horner, K. A., Gilbert, Y. E., and Cline, S. D. (2010). "Multiple high doses of methamphetamine increase malond-ialdehyde immunoreactivity in the nigrostriatal and mesolimbic systems of rat brain," in Paper Presented at the Triennial International Basal Ganglia Society Meeting, Long Branch.
25. Horner, K. A., Westwood, S. C., Hanson, G. R., and Keefe, K. A. (2006). Multiple high doses of methamphetamine increase the number of preproneu-ropeptide Y mRNA-expressing neurons in the striatum of rat via a dopamine D1 receptor-dependent mechanism. J. Pharmacol. Exp. Ther. 319, 414-421.
26. Hotchkiss, A. J., and Gibb, J. W. (1980). Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J. Pharmacol. Exp. Ther. 214, 257-262.
27. Jayanthi, S., Ladenheim, B., and Cadet, J. L. (1998). Methamphetamine-induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice. Ann. N. Y. Acad. Sci. 844, 92-102.
28. Jinsmaa, Y., Florang, V. R., Rees, J. N., Anderson, D. G., Strack, S., and Doorn, J. A. (2009). Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem. Res. Toxicol. 22, 835-841.
29. Johnson-Davis, K. L., Hanson, G. R., and Keefe, K. A. (2002). Long-term post-synaptic consequences of methamphetamine on preprotachykinin mRNA expression. J. Neurochem. 82, 1472-1479.
30. Kim, H.-C., Jhoo, W.-K., Choi, D.-Y., Im, D.-H., Shin, E.-J., Suh, J.-H., Floyd, R. A., and Bing, G. (1999). Protection of methamphetamine nigrostriatal toxicity by dietary selenium. Brain Res. 851, 76-86.
31. Kita, T., Shimada, K., Mastunari, Y., Wagner, G. C., Kubo, K., and Nakashima, T. (2000). Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology 39, 399-406.
32. Kogan, F. J., Nichols, W. K., and Gibb, J. W. (1976). Influence of methamphet- amine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur. J. Pharmacol. 36, 363-371.
33. Korf, J., Zieleman, M., and Westerlnk, B. H. C. (1976). Dopamine release in the substantia nigra? Nature 260, 257-258.
34. Krasnova, I. N., and Cadet, J. L. (2009). Methamphetamine toxicity and the messengers of death. Brain Res. Rev. 60, 397-407.
35. Lavoie, M. J., and Hastings, T. G. (1999). Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19, 1484-1491.
36. Lieberman, M., and Marks, A. D. (2009). Marks' Basic Medical Biochemistry: A Clinical Approach, Baltimore, MD: Lippincott Williams & Wilkins.
37. Long, J., Liu, C., Sun, L., Gao, H., and Liu, J. (2009). Neuronal mitochondrial toxicity of malondialdehyde: inhibitory effects on respiratory function and enzyme activities in rat brain mitochondria. Neurochem. Res. 34, 786-794.
38. Manzer, R., Qamar, L., Estey, T., Pappa, A., Petersen, D. R., and Vasiliou, V. (2003). Molecular cloning and baculo-virus expression of the rabbit corneal aldehyde dehydrogenase (ALDH1A1) cDNA. DNA Cell Biol. 22, 329-338.
39. Marchitti, S. A., Deitrich, R. A., and Vasiliou, V. (2007). Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism by 4-hydroxy-2-nonenal. Pharmacol. Rev. 59, 125-150.
40. Maxwell, J. C. (2005). Emerging research on methamphetamine. Curr. Opin. Psychiatry 18, 235-242.
41. McCaffery, P., and Drager, U. C. (1994). High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. Proc. Natl. Acad. Sci. U.S.A. 91, 7772-7776.
42. McEwen, B. (1999). Stress and hippocam-pal plasticity. Annu. Rev. Neurosci. 22, 105-122.
43. Moore, K., and Roberts, L. J. II. (1998). Measurement of lipid peroxidation. Free Radic. Res. 28, 659-671.
44. Pu, C., Broening, H. W., and Vorhees, C. V. (1996). Effect of methamphetamine on glutamate-positive neurons in the adult and developing rat somatosen-sory cortex. Synapse 23, 328-334.
45. Rau, K. S., Birdsall, E., Volz, T. J., Riordan, J. A., Baucum, A. J. I., Adair, B. P., Bitter, R., Gibb, J. W., Hanson, G. R., and Fleckenstein, A. E. (2006). Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake. J. Pharmacol. Exp. Ther. 318, 676-682.
46. Ricaurte, G. A., Fuller, R. W., Perry, K. W., Seiden, L. S., and Schuster, C. R. (1983). Fluoxetine increases long-lasting neostriatal dopamine depletion after administration of d-metham- phetamine and d-amphetamine. Neuropharmacology 22, 1165-1169.
47. Ricaurte, G. A., Schuster, C. R., and Seiden, L. S. (1980). Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 193, 153-163.
48. Robertson, G. S., Damsma, G., and Fibiger, H. C. (1991). Characterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats. J. Neurosci. 11, 2209-2216.
49. Rooke, N., Li, D.-J., Li, J., and Keung, W. M. (2000). The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin. J. Med. Chem. 43, 4169-4179.
50. Scatton, B., Javoy-Agid, F., Rouquier, L., Dubois, B., and Agid, Y. (1983). Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275, 321-328.
51. Seiden, L. S., and Ricuarte, G. A. (1987). "Neurotoxicity of methamphetamine and related drugs," in Psychopharmacology: The Third Generation of Progress, ed. H. Meltzer (New York: Raven Press), 359-366.
52. Simpson, J. N., Wang, J. Q., and McGinty, J. F. (1995). Repeated amphetamine admin- istration induces a prolonged augmentation of phosphorylated cyclase response element-binding protein and fos-related antigen immunoreactivity in rat striatum. Neuroscience 69, 441-457.
53. Sternberger, L. (1979). The unlabeled antibody (PAP) method, introduction. J. Histochem. Cytochem. 27, 1657.
54. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. (2010). The DAWN Report: Emergency Department Visits Involving Methamphetamine: 2004 to 2008. Rockville, MD: Drug Abuse Warning Network.
55. Thompson, P. M., Hayashi, K. M., Simon, S. L., Geaga, J. A., Hong, M. S., Sui, Y., Lee, J. Y., Toga, A. W., Ling, W., and London, E. D. (2004). Structural abnormalities in the brains of human subjects who use methamphetamine. J. Neurosci. 24, 6028-6036.
56. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Franscechi, D., Sedler, M. J., Gatley, S. J., Hintzemann, R., Ding, Y. S., and Wong, C. (2001). Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am. J. Psychiatry 158, 383-389.
57. Windels, F., and Kiyatkin, E. A. (2006). Dopamine action in the substantia pars reticulata: iontophoretic studies in awake, unrestrained rats. Eur. J. Neurosci. 24, 1385-1394.
58. Wrona, M. A., and Dryhurst, G. (2001). A putative metabolite of serotonin, tryptamine-4,5-dione, is an irreversible inhibitor of tryptophan hydroxylase: possible relevance to the serotonergic neurotoxicity of methamphetamine. Chem. Res. Toxicol. 14, 1184-1192.
59. Yamamoto, B. K., and Bankson, M. G. (2005). Amphetamine neurotoxicity: cause and consequence of oxidative stress. Crit. Rev. Neurobiol. 17, 87-117.
60. Yamamoto, B. K., and Zhu, W. (1998). The effects of methamphetamine on the production of free radicals and oxidative stress. J. Pharmacol. Exp. Ther. 287, 107-114.